Bispecific antibodies and nanotechnology: a strategic alliance in cancer immunotherapy

Simple item page
dc.contributor.affiliation000000041762408X
dc.contributor.affiliationDepartment of Pharmacology, Centro Singular de Investigación en Medicina Molecular e Enfermidades Crónicas (CiMUS), Santiago de Compostela, A Coruña, Spain; Advanced Therapies Manufacturing Center, Galaria EPSS SA, Santiago de Compostela, Spain; Immuno-oncology and Immunotherapy Group, Hospital Universitario 12 de Octubre, Madrid, Madrid, Spain; Centro de Transfusion y Banco de Tejidos, Barcelona, Barcelona, Spain; IMDEA Nanociencia, Madrid, Madrid, Spain; Instituto de Investigación Sanitaria de Santiago de Compostela, Santiago de Compostela, Galicia, Spainen
dc.contributor.authorBattistini, E.
dc.contributor.authorLapuhs, P.
dc.contributor.authorJiménez, A.
dc.contributor.authorGarrido-Areal, S.
dc.contributor.authorRivas-Gómez, L.
dc.contributor.authorZagorac, I.
dc.contributor.authorÁlvarez-Vallina, L.
dc.contributor.authorAlonso Fernández, M.J.
dc.contributor.authorSanjurjo, L.
dc.date.accessioned2026-02-17T15:01:49Z
dc.date.available2026-02-17T15:01:49Z
dc.date.issued2025
dc.format.mimetypeapplication/pdfen
dc.identifier.doi10.1186/s12943-025-02501-9
dc.identifier.urihttps://hdl.handle.net/20.500.12614/4193
dc.issue.number292
dc.journal.titleMolecular Canceren
dc.language.isoenen
dc.relation.projectIDTEMPEB and PL acknowledge grants ED481A-2023-036 and ED481A-2022-237, respectively, \u2018Programa de ayudas a la etapa predoctoral\u2019 of Xunta de Galicia (Conseller\u00EDa de Cultura, Educaci\u00F3n, Formaci\u00F3n Profesional y Universidades o de la Agencia Gallega de Innovaci\u00F3n) 2023 and 2022. AJ acknowledges a grant (05-IN606D-2023-2542597) from Xunta de Galicia \u201CDoutoramentos industriais convocatoria 2023\u201D. SGA receives support from the grant PREP2023-000545 funded by MCIN and by ESF. LAV laboratory is funded by the MCIN/AEI (PID2023-148429OB-I00, PID2020-117323RB- I00, PDC2021-121711-I00, CPP2022-009762, CPP2022-009765, CPP2023-010827), the Carlos III Health Institute (ISCIII) with European Regional Development Fund (FEDER) cofinancing (DTS20/00089, PMPTA22/00167); the Asociaci\u00F3n Espa\u00F1ola contra el C\u00E1ncer (AECC) (PROYE19084ALVA and PRYGN234844ALVA), the CRIS Cancer Foundation (FCRIS-2021-0090 and FCRIS-2023-0070), the Fundaci\u00F3n \u2018\u2018La Caixa\u2019\u2019 (HR21-00761 project IL7R_LungCan), the Comunidad de Madrid (P2022/BMD-7225 Next Generation CART MAD), and the Fundaci\u00F3n FERO (BBASELGAFERO2024.01). LRG is supported by an Industrial PhD fellowship from Comunidad de Madrid (IND2023/BMD-28821). MJA receive support from Xunta de Galicia (ED431C 2021/17 and ED431G 2019/02) and AEl (PID2023-150416OB-I00, PLEC2022-009298) funded by MCIN/AEI and the \u201CEuropean Union NextGeneration EU/PRTR\u201D. LS is supported by INVES246233SANJ and SNRGS259729SANJ Fundaci\u00F3n Cient\u00EDfica Asociaci\u00F3n Espa\u00F1ola Contra el C\u00E1ncer, and thanks Fundaci\u00F3n San Rafael (PAI2024) for the support.
dc.rightsAtribución-NoComercial-SinDerivadas 3.0 España
dc.rights.accessRightsopen accessen
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/es/
dc.titleBispecific antibodies and nanotechnology: a strategic alliance in cancer immunotherapyen
dc.typeresearch articleen
dc.type.hasVersionVoRen
dc.volume.number24

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
s12943-025-02501-9.pdf
Size:
2.76 MB
Format:
Adobe Portable Document Format
Download

Collections

Publications